LUCD Lucid Diagnostics Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1799011 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.6%
TTM net income YoY8.9%
TTM EPS YoY—
Revenue 3-yr CAGR53.6%
Net income 3-yr CAGR—
Margins
Gross margin-16.5%
Operating margin-941.7%
Net margin-892.8%
FCF margin-953.3%
EBITDA margin-925.5%
Returns
ROE-305.6%
ROA-119.8%
ROIC (approx.)—
Asset turnover0.13x
Leverage & solvency
Liabilities / assets78.7%
Debt / equity0.00x
Current ratio1.20x
Interest coverage-3,011.88x
Cash quality & payout
Operating cash flow / net income1.06x
Accruals ratio7.4%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.20M | $1.47M | $1.26M | $1.50M | $1.21M | $1.16M | $828,000 | $1.20M |
| Cost of revenue | $1.40M | $1.45M | $1.62M | $1.86M | $1.70M | $1.56M | $1.55M | — |
| Gross profit | -$201,000 | $29,000 | -$369,000 | -$356,000 | -$486,000 | -$400,000 | -$723,000 | — |
| R&D expense | $1.18M | $1.19M | $1.21M | $1.72M | $1.27M | $1.25M | $1.43M | $1.45M |
| SG&A expense | $5.54M | $5.76M | $5.43M | $6.48M | $5.61M | $5.62M | $6.16M | $5.86M |
| Operating income | -$12.28M | -$12.80M | -$12.11M | -$14.01M | -$11.76M | -$11.38M | -$12.49M | -$12.38M |
| Interest expense | $1,000 | $4,000 | $6,000 | $6,000 | $2,000 | $6,000 | $9,000 | $7,000 |
| Pretax income | -$6.68M | -$11.69M | -$13.91M | -$16.27M | -$10.40M | -$4.44M | -$26.91M | -$11.54M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$6.68M | -$11.69M | -$13.91M | -$16.27M | -$10.40M | -$4.44M | -$26.91M | -$11.54M |
| EBITDA | -$12.05M | -$12.58M | -$11.89M | -$13.80M | -$11.54M | -$11.16M | -$12.27M | -$12.15M |
| EPS (basic) | -0.03 | -0.08 | -0.17 | — | -0.10 | -0.08 | -0.52 | — |
| EPS (diluted) | — | — | — | — | -0.10 | -0.08 | -0.52 | — |
| Weighted avg. shares (diluted) | — | — | — | — | 108.18M | 98.99M | 68.80M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $17.99M | $33.40M | $27.88M | $34.70M | $47.33M | $31.12M | $25.24M | $22.36M |
| Receivables | $843,000 | $1.09M | $689,000 | $643,000 | $550,000 | $373,000 | $61,000 | $45,000 |
| Inventory | $520,000 | $484,000 | $469,000 | $353,000 | $486,000 | $505,000 | $484,000 | $341,000 |
| Current assets | $25.96M | $36.62M | $31.36M | $37.47M | $49.84M | $33.83M | $27.54M | $25.15M |
| PP&E, net | $706,000 | $810,000 | $907,000 | $809,000 | $862,000 | $948,000 | $1.04M | $1.06M |
| Intangibles | $0 | $105,000 | $210,000 | $315,000 | $421,000 | $526,000 | $631,000 | $736,000 |
| Total assets | $27.86M | $38.95M | $34.08M | $40.45M | $53.20M | $38.67M | $32.80M | $30.71M |
| Current liabilities | $21.65M | $27.52M | $29.39M | $28.58M | $26.21M | $29.43M | $36.57M | $23.52M |
| Total liabilities | $21.93M | $28.02M | $30.08M | $29.51M | $27.36M | $30.81M | $38.17M | $25.32M |
| Shareholders' equity | $5.93M | $10.93M | $4.00M | $10.94M | $25.84M | $7.86M | -$5.38M | $5.39M |
| Shares outstanding | 190.97M | 190.76M | 164.88M | 131.10M | 130.92M | 101.83M | 84.37M | 63.07M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.55M | -$11.30M | -$12.10M | -$12.58M | -$10.89M | -$10.55M | -$12.46M | -$9.87M |
| Capital expenditure | $17,000 | $21,000 | $215,000 | $51,000 | $28,000 | $25,000 | $93,000 | — |
| Free cash flow | -$15.57M | -$11.32M | -$12.32M | -$12.63M | -$10.92M | -$10.57M | -$12.56M | — |
| Investing cash flow | -$17,000 | -$21,000 | -$215,000 | -$51,000 | -$28,000 | -$25,000 | -$93,000 | -$259,000 |
| Financing cash flow | $156,000 | $16.85M | $5.49M | $2,000 | $27.13M | $16.46M | $15.44M | $18.00M |
| Depreciation & amortization | $225,000 | $224,000 | $222,000 | $209,000 | $220,000 | $222,000 | $221,000 | $222,000 |
| Stock-based compensation | $1.45M | $1.69M | $1.41M | $1.26M | $1.15M | $1.14M | $1.03M | $1.50M |
Free plan shows the latest 8 periods; Pro shows all 25 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.